
Please try another search
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Stephen George Dilly | 64 | 2020 | President, CEO & Chairman |
Dennis P. Wolf | 72 | 2007 | Independent Director |
James J. Lalonde | 64 | 2004 | Member of Strategic Advisory Board |
H. Stewart Parker | 69 | 2022 | Independent Director |
David V. Smith | 65 | 2016 | Lead Independent Director |
Carole Beth Cobb | 67 | 2024 | Member of Strategic Advisory Board |
Arthur A. Levin | 71 | 2025 | Member of Strategic Advisory Board |
Masad J. Damha | - | 2024 | Member of Strategic Advisory Board |
Rahul Singhvi | 60 | 2022 | Independent Director |
John M. Maraganore | 63 | 2024 | Member of Strategic Advisory Board |
Raymond De Vre | 57 | 2024 | Director |
Christos Richards | 68 | 2025 | Director |
Cynthia L. Collins | 67 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review